Sofinnova Partners has been investing for more than a decade in early-stage companies that use biotechnology to make a positive environmental impact. Every year, we witness progress as we work with scientists, engineers and entrepreneurs to build successful companies.
Quantifying environmental impact is challenging, especially with early-stage companies. Instead of projecting or forecasting, we focus on setting our portfolio companies on the right track and finding the most effective ways to monitor their progress over our investment holding period.
In this annual impact report, our second, you will read about how we strive to achieve impact in four of the 17 UN Sustainable Development Goals (SDGs), and how we set Key Performance Indicators (KPIs) that are just the right mix of environmental, technical and business targets.
This year's report goes deeper into our strategy as investors and provides more fine-grained detail on a selection of our innovative portfolio companies.
You will read about how we embed impact in every stage of our investment process and see breakdowns of our portfolio in terms of the SDGs the companies are addressing, and the sectors they are targeting.
The report goes deep on a handful of the companies, including our most recent investments. You'll see what some of the CEOs say about us and explore some truly fascinating technology — all of it inspired by the natural world.
Click on the link at the top of this page for an exciting read on how our industrial biotech strategy is curing the planet, one startup at a time!
Sofinnova Partners welcomes Andrew M. Weiss as Venture Partner
Sofinnova Partners and Gustave Roussy forge strategic alliance to boost oncology startup acceleration in France
Sofinnova Partners launches Biovelocita, the first Pan-European investment strategy dedicated to the creation and acceleration of biotech startups
Sofinnova Partners unveils Sofinnova.AI: A cutting-edge artificial intelligence platform set to transform its life sciences investment practice
Sofinnova Partners enhances leadership in Medtech acceleration with key appointments